Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 7:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2425–2448 of 14,147 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Depression, Anxiety, Insomnia, Substance Abuse
Interventions: TES Treatment, TES-SHAM Treatment; Device
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Belle Mead, New Jersey

Conditions: Multiple Sclerosis
Interventions: Avonex and Topamax; Drug
Lead sponsor: Multiple Sclerosis Institute; Other
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Systemic Lupus Erythematosus
Interventions: Obinutuzumab, Placebo, Acetaminophen/Paracetamol, Diphenhydramine hydrochloride, Methylprednisolone; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 14
States / cities: Anniston, Alabama • Searcy, Arkansas • Fullerton, California + 11 more

Conditions: Contraception
Interventions: NES/EE CVR; Combination Product
Lead sponsor: Population Council; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 1,135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2014
U.S. locations: 5
States / cities: Los Angeles, California • San Francisco, California • Chicago, Illinois + 2 more

Conditions: Diabetic Gastroparesis, Idiopathic Gastroparesis
Interventions: NG101, Placebo; Drug
Lead sponsor: Neurogastrx, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 83
States / cities: Dothan, Alabama • Foley, Alabama • Mobile, Alabama + 69 more

Conditions: Non-cystic Fibrosis Bronchiectasis
Interventions: Galvokimig, Placebo; Biological
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 7
States / cities: Newport Beach, California • Brandon, Florida • Plantation, Florida + 4 more

Conditions: Type 2 Diabetes
Interventions: Placebo, BMS-820132; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 5
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Miami, Florida + 1 more

Conditions: CMV Disease
Interventions: Letermovir, Valganciclovir, Acyclovir (ACV), Placebo to ACV, Placebo to LET, Placebo to VGCV; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 27
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 21 more

Conditions: Venezuelan Equine Encephalitis Virus Infection
Interventions: Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate, 0.9% saline placebo; Biological · Other
Lead sponsor: Ichor Medical Systems Incorporated; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: San Diego, California

Conditions: COVID-19
Interventions: Flu Seasonal /SARS-CoV-2 mRNA Dose 1, Flu Seasonal /SARS-CoV-2 mRNA Dose 2, Flu Seasonal mRNA, SARS-CoV-2 mRNA Dose 1, SARS-CoV-2 mRNA Dose 2, Licensed Flu Seasonal, Licensed COVID-19 mRNA, Placebo; Combination Product · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 9
States / cities: Anniston, Alabama • Rolling Hills Estates, California • Hialeah, Florida + 5 more

Conditions: Cystic Fibrosis
Interventions: VX-661, Ivacaftor, Placebo matched to VX-661, Placebo matched to ivacaftor; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 19
States / cities: Birmingham, Alabama • Oakland, California • Boise, Idaho + 16 more

Conditions: Covid19, Coronavirus, Coronavirus Infection, Corona Virus Infection
Interventions: Ebselen, Placebo; Drug
Lead sponsor: Sound Pharmaceuticals, Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 7
States / cities: New Haven, Connecticut • Boise, Idaho • Kansas City, Kansas + 4 more

Conditions: Neuromuscular Blockade
Interventions: Sugammadex 2 mg/kg ABW, Sugammadex 2 mg/kg IBW, Sugammadex 4 mg/kg ABW, Sugammadex 4 mg/kg IBW, Neostigmine + Glycopyrrolate, Rocuronium or Vecuronium; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 13
States / cities: Sacramento, California • Miami, Florida • Kansas City, Kansas + 9 more

Conditions: Obesity
Interventions: oleoyl-estrone (MP 101); Drug
Lead sponsor: Manhattan Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 2
States / cities: Baton Rouge, Louisiana • Salt Lake City, Utah

Conditions: Anklyosing Spondylitis
Interventions: Secukinumab (75 mg), Placebo, Secukinumab (150 mg); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 10
States / cities: Mesa, Arizona • Upland, California • Edina, Minnesota + 6 more

Conditions: Fibromyalgia Syndrome
Interventions: Lacosamide, Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 25
States / cities: Litchfield Park, Arizona • Santa Ana, California • Walnut Creek, California + 21 more

Conditions: Uterine Fibroids
Interventions: Proellex, placebo; Drug · Other
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 48 Years · Female only
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 17
States / cities: Anaheim, California • Los Angeles, California • Miami, Florida + 10 more

Conditions: Mothers
Interventions: Text-based mentorship, Control text messaging; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 199 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Sedentary Lifestyle, Occupational Exposure, Health Behavior, Safety Issues
Interventions: Total Worker Health, Control; Behavioral · Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 264 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Colitis Ulcerative, Ulcerative Colitis
Interventions: MK-8690, Placebo; Drug · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 11
States / cities: Anaheim, California • Coronado, California • Colorado Springs, Colorado + 8 more

Conditions: Frailty, Inflammation
Interventions: Epigallocatechin-3-Gallate (EGCG) plus Ascorbic Acid (Vitamin C); Drug
Lead sponsor: University of Rochester; Other
Eligibility: 65 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Chronic Low Back Pain
Interventions: PF-06372865, Placebo, Naproxen; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 46
States / cities: Mesa, Arizona • Phoenix, Arizona • Anaheim, California + 36 more

Conditions: Primary Dysmenorrhea
Interventions: VA111913 TS and placebo; Drug
Lead sponsor: Vantia Ltd; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Peoria, Arizona • Austin, Texas • Salt Lake City, Utah

Conditions: Breast Cancer, High Risk of Breast Cancer
Interventions: da Vinci SP Surgical System; Device
Lead sponsor: Deborah Farr, MD; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

Nexalin Therapy as a Viable Adjunctive Treatment for Substance Use Disorders

A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

Safety and Efficacy of a Contraceptive Vaginal Ring Delivering Nestorone® and Ethinyl Estradiol

A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis

A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis

Multiple Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes

Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)

Study of a DNA-based Venezuelan Equine Encephalitis Virus DNA Vaccine Administered by Electroporation in Healthy Volunteers

A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults

Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation

SPI-1005 Treatment in Severe COVID-19 Patients

Efficacy and Safety of Sugammadex Dosed According to Actual Body Weight (ABW) or Ideal Body Weight (IBW) in Reversal of Neuromuscular Blockade (NMB) in Morbidly Obese Participants (MK-8616-146)

Phase 2a Obesity Study of Oral Doses of Oleoyl-Estrone (MP-101)

16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis

Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome.

Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids

Virtual Mentorship to Support Maternal and Infant Health and Wellbeing: Assessing the Impact and Efficacy of NurturePA

Active Workplace Study

A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

Reducing Frailty for Older Cancer Survivors Using Supplements

PF-06372865 In Subjects With Chronic Low Back Pain

VA111913 Dysmenorrhoea Efficacy and Safety Proof of Concept

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy